AAV-based Gene Delivery of Antimicrobial Peptides to Combat Drug-resistant Pathogens

Overview

Journal Appl Environ Microbiol

Specialties Environmental Health
Microbiology

Date 2025 Jan 6

PMID 39760495

Authors

Piyush Baindara

Dinata Roy

Chandra S Boosani

Santi M Mandal

Jonathan A Green

Affiliations

Soon will be listed here.

Abstract

Antimicrobial peptides (AMPs) have emerged as potential alternatives to conventional antibiotics due to their novelty and multiple mechanisms of action. Because they are peptides, AMPs are amenable to bioengineering and suitable for cloning and expression at large production scales. However, the efficient delivery of AMPs is an unaddressed issue, particularly due to their large size, possible toxicities, and the development of adverse immune responses. Here, we have reviewed the possibilities of adeno-associated virus (AAV)-based localized gene delivery of AMPs for the treatment of infectious diseases with a special focus on respiratory infections. By discussing the gene delivery mechanism of AAV and the accompanying technical and therapeutic challenges with AMPs, we describe a foundation that emphasizes the use of viral vector-based gene delivery of AMPs for disease treatment.

References

Limberis M, Adam V, Wong G, Gren J, Kobasa D, Ross T . Intranasal antibody gene transfer in mice and ferrets elicits broad protection against pandemic influenza. Sci Transl Med. 2013; 5(187):187ra72. PMC: 4596530. DOI: 10.1126/scitranslmed.3006299. View

Wang D, Tai P, Gao G . Adeno-associated virus vector as a platform for gene therapy delivery. Nat Rev Drug Discov. 2019; 18(5):358-378. PMC: 6927556. DOI: 10.1038/s41573-019-0012-9. View

Ghosh C, Sarkar P, Issa R, Haldar J . Alternatives to Conventional Antibiotics in the Era of Antimicrobial Resistance. Trends Microbiol. 2019; 27(4):323-338. DOI: 10.1016/j.tim.2018.12.010. View

Schuster B, Kim A, Kays J, Kanzawa M, Guggino W, Boyle M . Overcoming the cystic fibrosis sputum barrier to leading adeno-associated virus gene therapy vectors. Mol Ther. 2014; 22(8):1484-1493. PMC: 4435598. DOI: 10.1038/mt.2014.89. View

Chandler L, Barnard A, Caddy S, Patricio M, McClements M, Fu H . Enhancement of Adeno-Associated Virus-Mediated Gene Therapy Using Hydroxychloroquine in Murine and Human Tissues. Mol Ther Methods Clin Dev. 2019; 14:77-89. PMC: 6606965. DOI: 10.1016/j.omtm.2019.05.012. View

Griesenbach U, Pytel K, Alton E . Cystic Fibrosis Gene Therapy in the UK and Elsewhere. Hum Gene Ther. 2015; 26(5):266-75. PMC: 4442579. DOI: 10.1089/hum.2015.027. View

Xiao Y, Muhuri M, Li S, Qin W, Xu G, Luo L . Circumventing cellular immunity by miR142-mediated regulation sufficiently supports rAAV-delivered OVA expression without activating humoral immunity. JCI Insight. 2019; 5. PMC: 6629123. DOI: 10.1172/jci.insight.99052. View

Nieto K, Salvetti A . AAV Vectors Vaccines Against Infectious Diseases. Front Immunol. 2014; 5:5. PMC: 3896988. DOI: 10.3389/fimmu.2014.00005. View

Leborgne C, Barbon E, Alexander J, Hanby H, Delignat S, Cohen D . IgG-cleaving endopeptidase enables in vivo gene therapy in the presence of anti-AAV neutralizing antibodies. Nat Med. 2020; 26(7):1096-1101. DOI: 10.1038/s41591-020-0911-7. View

10.

Zabaleta N, Dai W, Bhatt U, Herate C, Maisonnasse P, Chichester J . An AAV-based, room-temperature-stable, single-dose COVID-19 vaccine provides durable immunogenicity and protection in non-human primates. Cell Host Microbe. 2021; 29(9):1437-1453.e8. PMC: 8346325. DOI: 10.1016/j.chom.2021.08.002. View

11.

Falese L, Sandza K, Yates B, Triffault S, Gangar S, Long B . Strategy to detect pre-existing immunity to AAV gene therapy. Gene Ther. 2017; 24(12):768-778. PMC: 5746592. DOI: 10.1038/gt.2017.95. View

12.

Dinata R, Baindara P . Laterosporulin25: A probiotically produced, novel defensin-like bacteriocin and its immunogenic properties. Int Immunopharmacol. 2023; 121:110500. DOI: 10.1016/j.intimp.2023.110500. View

13.

Zhang Q, Yu Y, Velasquez J, van der Donk W . Evolution of lanthipeptide synthetases. Proc Natl Acad Sci U S A. 2012; 109(45):18361-6. PMC: 3494888. DOI: 10.1073/pnas.1210393109. View

14.

Jacobsen F, Mittler D, Hirsch T, Gerhards A, Lehnhardt M, Voss B . Transient cutaneous adenoviral gene therapy with human host defense peptide hCAP-18/LL-37 is effective for the treatment of burn wound infections. Gene Ther. 2005; 12(20):1494-502. DOI: 10.1038/sj.gt.3302568. View

15.

Colella P, Ronzitti G, Mingozzi F . Emerging Issues in AAV-Mediated Gene Therapy. Mol Ther Methods Clin Dev. 2018; 8:87-104. PMC: 5758940. DOI: 10.1016/j.omtm.2017.11.007. View

16.

Hareendran S, Balakrishnan B, Sen D, Kumar S, Srivastava A, Jayandharan G . Adeno-associated virus (AAV) vectors in gene therapy: immune challenges and strategies to circumvent them. Rev Med Virol. 2013; 23(6):399-413. DOI: 10.1002/rmv.1762. View

17.

Huang X, Yang Y . Innate immune recognition of viruses and viral vectors. Hum Gene Ther. 2009; 20(4):293-301. PMC: 2858295. DOI: 10.1089/hum.2008.141. View

18.

Baindara P, Singh N, Ranjan M, Nallabelli N, Chaudhry V, Pathania G . Laterosporulin10: a novel defensin like Class IId bacteriocin from Brevibacillus sp. strain SKDU10 with inhibitory activity against microbial pathogens. Microbiology (Reading). 2016; 162(8):1286-1299. DOI: 10.1099/mic.0.000316. View

19.

Carretero M, Del Rio M, Garcia M, Escamez M, Mirones I, Rivas L . A cutaneous gene therapy approach to treat infection through keratinocyte-targeted overexpression of antimicrobial peptides. FASEB J. 2004; 18(15):1931-3. DOI: 10.1096/fj.04-1515fje. View

20.

Bulcha J, Wang Y, Ma H, Tai P, Gao G . Viral vector platforms within the gene therapy landscape. Signal Transduct Target Ther. 2021; 6(1):53. PMC: 7868676. DOI: 10.1038/s41392-021-00487-6. View